GLAXO PLANS TO MAKE MUMBAI PLANT GLOBAL HUB

A A

Glaxo SmithKline Pharmaceuticals Plc is planning to make GSK India's Thane manufacturing facility a global sourcing hub for active pharma ingredient (API) for its top-selling steroid betamethasone. The plant is currently manufacturing this product for the domestic market. Once it is converted into a global hub, the facility will supply this API to 40 markets world-wide except the US. Currently, betamethasone in bulk is manufactured by GSK Plc at its UK plant for global requirements.

Business Standard (http://www.business-standard.com/common/storypage.php?hpFlag=Y&chklogin=N&autono=208728&leftnm=lmnu1&lselect=0&leftindx=1)